NASDAQ: EIGR Received A “Sell” Rating From Stock Market Analysts
Eiger BioPharmaceuticals received a downgrade to a rating of “sell” from a rating of “Buy” from stock market analysts during a Tuesday report. NASDAQ: EIGR operates as a drug manufacturer and therapy treatment developer for orphan diseases. Formerly, the company was called Celladon Corporation. It is located in California.
What Do Stock Market Analysts Say About NASDAQ: EIGR Ratings?
LADENBURG THALM/ SH SH announced a rating of “buy” and a target price of $28.00 on NASDAQ: EIGR shares on 29th September during a Tuesday report. Wedbush announced a rating of “buy” and a price target of $32.00 on Eiger BioPharmaceuticals shares on 1st September during a Tuesday report. Lastly, BidaskClub increased its Eiger BioPharmaceuticals (NASDAQ: EIGR) holdings to a rating of “hold” from a rating of “sell” during a Friday report.
One stock market analyst issued a rating of “sell” to Eiger BioPharmaceuticals (NASDAQ: EIGR). Meanwhile, two stock market analysts issued a rating of ”hold” and free issued a rating of “Buy”. Overall, Eiger BioPharmaceuticals has an average “hold” rating and a target price of $23.00.
On Tuesday, Eiger BioPharmaceuticals Stock started trading at $0.02. The company’s one year low and one year high are $4.55 and $15.82. NASDAQ: EIGR also reported a quick ratio, current ratio, and debt to equity ratio of 6.03, 6.03, and 0.47 respectively. The firm’s market capitalization is $297.11 million. The firm’s beta and PE ratio stand at 1.59 and -3.81 respectively. The company’s 50 days moving average and 200 days moving average as $9.51 and $10.00 respectively.
Which Hedge Funds Increased Or Decreased Its Eiger BioPharmaceuticals Holdings Recently?
BNP Paribas Arbitrage SA increased its Eiger BioPharmaceuticals (NASDAQ: EIGR) Holdings by 167.1 percent for the first quarter. They currently own an estimate of $49,000, which comes from 7,213 company shares. Man Group plc recently acquired Eiger BioPharmaceuticals (NASDAQ: EIGR) shares for the second quarter weigh $117,000.
Similarly, SG Americas Securities LLC also acquired NASDAQ: EIGR shares worth $127,000 for the second quarter. Alliancebernstein LP increased its Eiger BioPharmaceuticals Holdings by 87.4 percent for the first quarter. They currently own an estimate of $131,000, which comes from 19,300 company shares. Lastly, Virtu Financial LLC acquired new NASDAQ: EIGR shares worth $139,000 for the second quarter.
It should be noted that 66.62 percent of Eiger BioPharmaceuticals (NASDAQ: EIGR) Stock is under hedge funds and stock market institutional investors.
On 6th August, during a Thursday report, Eiger BioPharmaceuticals (NASDAQ: EIGR) revealed its earnings for the quarter. As per reports, the company brought in $0.60 EPS, surpassing Zacks’ estimate of $0.71 EPS. Stock market analysts further predicted that NASDAQ: EIGR will bring in -1.31 earnings per share for this year.
The post NASDAQ: EIGR Received A “Sell” Rating From Stock Market Analysts first appeared on Digital Market News.
Read The Full Article
This Content Was Originally Posted At: